Records containing: NSCLC
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2023-06-05Breathomics as a Non-invasive, Inexpensive, Point-of-care Predictive Test for Immune Checkpoint Inhibitor Efficacy
-
CLINICAL_TRIALS study record update · 2023-05-26A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC
-
CLINICAL_TRIALS study record update · 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
-
CLINICAL_TRIALS study record update · 2023-04-14The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
-
CLINICAL_TRIALS study record update · 2023-04-14A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-03-21Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
-
CLINICAL_TRIALS study record update · 2023-03-17Minimal Residual Disease (MRD)-Guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB Non-small Cell Lung Cancer (NSCLC): a Randomized Controlled Phase II Study (Seagull)
-
CLINICAL_TRIALS study record update · 2023-03-06Phase 1 Study of Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2023-03-01EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer: A Feasibility Study
-
CLINICAL_TRIALS study record update · 2023-02-24A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
CLINICAL_TRIALS study record update · 2023-02-21A Randomised Non-comparative, Phase II Study Investigating the Best Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Sequence in Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Harboring EGFR Mutations
-
CLINICAL_TRIALS study record update · 2023-02-15A Prospective, Single-arm, Observational Clinical Study Based on 18F-FDG PET/CT to Evaluate the True Efficacy and Immune Response of PD-1 Monoclonal Antibody Combined With First-line Chemotherapy in Advanced Non-small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2023-01-19Efficacy and Safety Analysis of Immune Checkpoint Inhibitors Plus Angiogenesis Inhibitors for Treatment of Advanced Driver-negative NSCLC in Elderly Patients：A Retrospective Study
-
CLINICAL_TRIALS study record update · 2023-01-12A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor
-
CLINICAL_TRIALS study record update · 2022-12-23Almonertinib Plus Metronomic Oral Vinorelbine Beyond Limited Progression on Third-generation TKI in EGFR-mutant Advanced NSCLC，an Observational Study
-
CLINICAL_TRIALS study record update · 2022-12-21A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
-
CLINICAL_TRIALS study record update · 2022-12-15Milciclib in Combination With Gemcitabine in Advanced Non-Small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2022-11-23Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
-
CLINICAL_TRIALS study record update · 2022-11-09PD-1 Antibody in Addition to Bronchial Arterial Chemoembolization in Patients With Non-Small-Cell Lung Cancer: A Randomised Controlled Trial
-
CLINICAL_TRIALS study record update · 2022-11-02A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.
-
CLINICAL_TRIALS study record update · 2022-10-21A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2022-10-13SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases From Non-small Cell Lung Cancer, an Open, Randomized Phase II Study
-
CLINICAL_TRIALS study record update · 2022-09-27A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)
-
CLINICAL_TRIALS study record update · 2022-09-21Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2022-09-19A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors